Revolution Medicines Inc
F:42Z
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Revolution Medicines Inc
F:42Z
|
US |
|
M
|
Mitsubishi Estate Co Ltd
XMUN:MES
|
JP |
|
N
|
Novo Nordisk A/S
XMUN:NOVA
|
DK |
|
C
|
Calgro M3 Holdings Ltd
JSE:CGR
|
ZA |
|
A
|
Aecon Group Inc
F:2AE
|
CA |
|
E
|
ENRG Elements Ltd
OTC:EELFF
|
AU |
|
International Petroleum Corp
F:IPT
|
CA |
Intrinsic Value
Is 42Z undervalued or overvalued?
See the intrinsic value estimate for 
Revolution Medicines Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
42Z looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with 42Z’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Revolution Medicines Does
Revolution Medicines is a biotechnology company that develops cancer drugs aimed at one of the hardest drug targets in oncology: the RAS signaling pathway. Its lead programs are designed to block specific RAS mutations, especially those found in tumors such as pancreatic, lung, and colorectal cancers. The company does not sell consumer products; it is building prescription medicines that oncologists would use in hospital and clinic settings.
- Headquarters
- United States of America US
- Employees
- 883
- IPO date
- Feb 13, 2020
Revolution Medicines has no economic moat
Protecting a particular medicine does not prevent other companies from developing different treatments for the same cancers. Revolution Medicines faces competing drug developers, without an established production-cost advantage that rivals cannot match.
Read the full moat analysis
Earnings Waterfall
Revolution Medicines Inc
The intrinsic value for Revolution Medicines Inc (42Z) under the Base Case is hidden EUR.
Compared with the current market price of 167 EUR, the stock appears hidden.